---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-010275"
form_type: "8-K"
ticker: "ENVB"
cik: "0000890821"
company_name: "Enveric Biosciences, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T12:02:29.948425+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Enveric Biosciences Q1 net loss narrows to $2.2M; progresses EB-003 IND timeline

## Summary
- Net loss $2.2M in Q1 2025 vs $2.5M in Q1 2024; diluted loss per share $1.22 vs $9.21.
- Cash and equivalents $4.3M at March 31, 2025, after closing $5M public offering.
- New U.S. patent for EVM401 Series (mescaline derivatives) and EB-003 IP expanded.
- Signed two licensing agreements for cannabinoid-COX-2 conjugates with Restoration Biologics.
- Targeting FDA IND submission for EB-003 by end of Q1 2026.

## SEC filing metadata
- accession: 0001641172-25-010275
- form_type: 8-K
- ticker: ENVB
- cik: 0000890821
- company_name: Enveric Biosciences, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/890821/000164117225010275/0001641172-25-010275-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/890821/000164117225010275/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-010275
- JSON: https://secwatch.observer/filing/0001641172-25-010275.json
- Plain text: https://secwatch.observer/filing/0001641172-25-010275.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.